Gsk Plc · LSE:GSK
Gsk — Investor Presentation (February 2016)
12 slides from Gsk's investor presentation, Feb 24, 2016
Slide 1: Immuno-Oncology
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 2016
Slide 2: Oncology R&D strategy
Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival & Reprogram Cancer Cures Cells GSK Pipeline Immuno-Oncology Stimulate Anti-Tumour First in Class Medicines Immunity & Combination Therapy Cancer Stem Cells & Targeted Therapies 2
Slide 3: Generations of therapies
3 Generations of therapies Generation 1 Generation 2 Generation 3 Multiple therapies Anti-PD-L1 under YERVOY KEYTRUDA ipilimumab (CTLA-4) pembrolizumab (PD-1) development 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 PROVENGE BLINCYTO sipuleucel-T blinatumomab (BITE) (Cell Therapy) CAR-Ts OPDIVO
Slide 4: Main trends
Main trends SOC Immune New replacements profiling technologies Elimination of chemotherapy Patient selection Expansion of the from SOC to predict toolbox regimens response 2016 CURE Substantial survival Complex improvements combinations Across wide Maximise efficacy populations Improved endpoints Ac
Slide 5: 3rd Generation opportunities
3rd Generation opportunities Spectrum of immuno-oncology modalities Adaptive Immunity Innate Immunity T-Cell Immunity B-Cell Immunity Cytokines Cellular Therapies - NK Cells Cancer Vaccines T-cell Checkpoint Modulators Checkpoint Modulators “Connector” Bi-specific Abs - Dual-specific Abs Small Molec
Slide 6: 3rd Generation opportunities: GSK's multi-modality pipeline
3rd Generation opportunities GSK’s multi-modality pipeline Adaptive Immunity Innate Immunity T-Cell Immunity B-Cell Immunity Cytokines Cellular Therapies - NK Cells* Cancer Vaccines T-cell Checkpoint Modulators Checkpoint Modulators “Connector” Bi-specific Abs - Dual-specific Abs Small Molecules Onc
Slide 7: 3rd Generation leadership
3rd Generation leadership Innovation across novel targets, modalities and combinations (5 in the clinic) Modality Program Mechanism Pre-clinical Phase 1 Phase 2 GSK3174998 OX40 agonist Solid Tumours, Heme Malignancies GSK3359609 ICOS agonist GSK2857916 BCMA -ADC Multiple Myeloma mAbs Brontictuzumab
Slide 8: NY-ESO T-Cell Therapy
NY-ESO T-Cell Therapy Sarcoma Phase I/II: Individual patient complete response (CR) • TCR T-cell therapy Baseline Day 2: Inflammation Day 100: CR • 50% ORR seen in sarcoma • Ongoing studies in ovarian and other solid tumours and haematological malignancies • Planned studies in combination 60 Sarcoma
Slide 9: GSK3174998 OX40 agonist mAb
GSK3174998 OX40 agonist mAb Survival in animal model (CT26) • GSK3174998 is one of four humanised OX-40s OX-40 + PD-1 100 in clinic Percent survival 80 • Dual mechanism: enhancing effector T-cell and 60 aOX40 /aPD-1 suppressing T-regs 40 20 aOX40 • Phase I Study started in eight cancers control aPD-
Slide 10: GSK3359609 first-in-class ICOS agonist antibody
GSK3359609 first-in-class ICOS agonist antibody • Universal mechanism across multiple ICOS in ipilimumab-treated patients GSK3359609 cancers 80 CD4 ICOS T cells T cell Activation in-vitro • Patient selection biomarker Cell count/L % of total CD4 T cells 100 CD69+ CD4 T cells 24hr after stimulation
Slide 11: GSK2857916 BCMA-ADC
GSK2857916 BCMA-ADC Bone Marrow Dissemination Model (SCID Mice) • B Cell Maturation Antigen • Antibody Drug Conjugate (ADC) with MMAF (auristatin derivative) • High-expression target in multiple myeloma • ADCC enhanced • Immunogenic cell death inducer • Strong pre-clinical activity • High potential
Slide 12: Immuno-Oncology at GSK
Immuno-Oncology at GSK Mission: Maximise patient survival Achieve a long-term leadership position in Oncology Scientific Focus Tactics Goals • Diversified pipeline • Optimise T-cell Immunity • Across key modalities • Transformational effects for Rationale: has delivered patients transformational med